Clinical trial
Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes
NCT00382200 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00382200 |
|---|---|
| Title | Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes |
| Official title | Phase I/II Study of Decitabine and All-Trans Retinoic Acid (Tretinoin) for Patients With Myelodysplastic Syndromes |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndromes |
| Intervention type | Drug, Genetic, Other |
| Interventions | decitabine, tretinoin, DNA methylation analysis, cytogenetic analysis, microarray analysis, flow cytometry, immunohistochemistry staining method |
| Enrollment | 54 |
| Start date | Jul 1, 2006 |
| Primary completion | Jan 5, 2023 |
| Completion | Jan 5, 2023 |
| First posted | Sep 28, 2006 |
| Last update posted | May 20, 2024 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: